Respiratory Syncytial Virus (RSV)
The study will include both participants who are otherwise healthy (ie, without underlying condition) or who have comorbid conditions (eg, asthma, chronic obstructive pulmonary disease (COPD), cardiovascular disease, other chronic diseases), with the exception of immunocompromised participants, presenting for medical care but not requiring hospitalization. The study will include a screening period (Day -1 to Day 1), a treatment Period (Day 1 to Day 8), and a follow-up period (Day 9 to Day 28). Safety evaluations will include adverse events, laboratory tests, electrocardiogram, vital signs, physical examination, and specific toxicities.
Therapeutic / Disease area: Infectious Disease, Influenza / Flu, Respiratory, Vaccines
Condition: Respiratory Infection
Locations: Blacktown (NSW), Kippa Ring (QLD), Wyong (NSW)
Commencement date: 01/07/2018
Status: Recruitment active